Drug Database
HO

Holoclar (GPLSCD 01 / Holoclar / GPLSCD01)

✓ Approved

Holostem Terapie Avanzate · 细胞治疗 · 细胞治疗

什么是 Holoclar?

Holoclar 是一种细胞治疗,由Holostem Terapie Avanzate研发。该药已获批,用于治疗相关适应症,给药途径:Intraocular Injection、Surgical Implantation。

药物档案

商品名GPLSCD 01, Holoclar, GPLSCD01
公司Holostem Terapie Avanzate
药物类别细胞治疗
给药途径Intraocular Injection, Surgical Implantation
状态Approved

治疗适应症

Holoclar 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Injury, poisoning and procedural complicationsInjury corneal✓ Approved
Eye disordersLimbal stem cell deficiency✓ Approved

相关研究文献

PubMedOphthalmology and therapy2025-12-04

Current Landscape and Future Prospects of Corneal Regenerative Medicine.

Giannaccare Giuseppe G, Lixi Filippo F, Slidsborg Carina C, Ozkan Gamze G et al.

Corneal disorders are among the leading causes of visual impairment worldwide, with corneal transplantation historically serving as the cornerstone of surgical treatment. However, the global shortage of donor tissue, risk of immune rejection, and variable long-term graft survival underscore the urgent need for alternative approaches, particularly in the setting of ocular surface diseases such as inflammation or dry eye that can compromise graft survival. Regenerative medicine has emerged as a transformative paradigm, offering strategies to restore corneal architecture and function through cell-based therapies, tissue engineering, and gene modulation. These strategies are promising, addressing structural repair and modulating wound-healing responses. In the corneal epithelium, cultivated limbal epithelial transplantation, simple limbal epithelial transplantation, and cultivated oral mucosal epithelial transplantation have expanded therapeutic options for limbal stem cell deficiency, with clinical trials demonstrating long-term ocular surface stability. Regulatory approval of commercial products, such as Holoclar and Nepic, confirms the potential of standardized regenerative products. Stromal regeneration with stromal and mesenchymal stem cells has shown promise in preclinical and early phase clinical trials, with intrastromal stem cell injection improving corneal transparency and biomechanics and potentially stabilizing progressive disorders such as keratoconus. For endothelial dysfunction, intracameral injection of cultured corneal endothelial cells supplemented with Rho-associated protein kinase (ROCK) inhibitors has yielded sustained corneal clarity and visual restoration at 5-10 years, marking a paradigm shift from transplantation to minimally invasive, donor-independent therapies. Tissue engineering innovations, including matrices, hydrogels, and three-dimensional bioprinting, are advancing toward translation, while gene therapy approaches using viral vectors and Clustered Regularly Interspaced Short Palindromic Repeats -Cas9 are being explored to modulate angiogenesis, fibrosis, and inherited dystrophies. Overall, regenerative medicine is reshaping corneal therapeutics, offering effective alternatives to conventional transplantation with reduced donor dependence and improved safety. Future work must focus on long-term safety, cost-effectiveness, and equitable global access to realize its full clinical potential.

PMID 41343141
阅读全文 →
PubMedRegenerative therapy2024-09-27

Status and prospects for the development of regenerative therapies for corneal and ocular diseases.

Takayanagi Hiroshi H, Hayashi Ryuhei R

Among the regenerative therapies being put into clinical use, the field of corneal regenerative therapy is one of the most advanced, with several regulatory approved products. This article describes the progress from initial development through to clinical application in the eye field, with a particular focus on therapies for corneal epithelial and endothelial diseases that have already been regulatory approved as regenerative therapy products. The applications of regenerative therapy to the corneal epithelium were attempted and confirmed earlier than other parts of the cornea, following advancements in basic research on corneal epithelial stem cells. Based on these advances, four regenerative therapy products for corneal epithelial disease, each employing distinct cell sources and culture techniques, have been commercialized since the regulatory approval of Holoclar® in Italy as a regenerative therapy product for corneal epithelial disease in 2015. Corneal endothelial regenerative therapy was started by the development of an in vitro method to expand corneal endothelial cells which do not proliferate in adults. The product was approved in Japan as Vyznova® in 2023. The development of regenerative therapies for retinal and ocular surface diseases is actively being pursued, and these therapies use somatic stem cells and pluripotent stem cells (PSCs), especially induced pluripotent stem cells (iPSCs). Accordingly, the eye field is anticipated to play a pioneering role in regenerative therapy development going forward.

PMID 39329098
阅读全文 →
PubMedAdvances in experimental medicine and biology2023-06-01

Illustrative Potency Assay Examples from Approved Therapies.

Torrents Sílvia S, Grau-Vorster Marta M, Vives Joaquim J

Advanced therapy medicinal products (ATMP) encompass a new type of drugs resulting from the manipulation of genes, cells, and tissues to generate innovative medicinal entities with tailored pharmaceutical activity. Definition of suitable potency tests for product release are challenging in this context, in which the active ingredient is composed of living cells and the mechanism of action often is poorly understood. In this chapter, we present and discuss actual potency assays used for the release of representative commercial ATMP from each category of products (namely, KYMRIAH® (tisagenlecleucel), Holoclar® (limbal epithelial stem cells), and PROCHYMAL®/RYONCIL™ (remestemcel-L)). We also examine concerns related to the biological relevance of selected potency assays and challenges ahead for harmonization and broader implementation in compliance with current quality standards and regulatory guidelines.

PMID 37258788
阅读全文 →
PubMedDie Ophthalmologie2022-08-05

[Regenerative medicine for the corneal epithelium : Cell therapy from bench to bedside].

Menzel-Severing Johannes J, Spaniol Kristina K, Groeber-Becker Florian F, Geerling Gerd G

In the case of thermal or caustic burns of the ocular surface, loss of limbal epithelial stem cells leads to compromised self-renewal of the corneal epithelium. This results in permanent loss of vision. In these situations, transplantation of cultured limbal epithelial cells on an amniotic membrane or fibrin gel as substrate (Holoclar®) can help to regenerate the corneal surface. The required cells are obtained from the healthy partner eye, if available. Adult stem cells from other parts of the body potentially serve as alternative cell sources: hair follicles, oral mucosa, mesenchymal stromal cells, or induced pluripotent stem cells (originally, e.g., skin fibroblasts). The reprogramming of such cells can be achieved with the help of transcription factors. In addition, work is being done on biosynthetic or synthetic matrices, which not only serve as substrate material for the transplantation but also support the functional properties of these cells (self-renewal, corneal epithelial-typical phenotype).

PMID 35925345
阅读全文 →
PubMedRevue medicale de Liege2021-11-06

[Holoclar®, an autologous stem cells graft for sight recovery after ocular burns].

Tilkin C C, Duchesne B B, Camby S S, P Pellegrini P

Ocular chemical or physical burns currently represent 12 % of domestic accidents in Europe. They can lead to numerous ophthalmologic sequelae ranging from simple superficial keratitis to conjunctival ischemia and the destruction of limbal corneal stem cells. This results in damages to the cornea which can progress to neovascularization and corneal invasion by conjunctival tissue. Long term consequences affect ocular function (sometimes blindness, stromal degradation, infections, or even ocular perforation). Until now, few treatments were available to restore corneal transparency after a trauma. Patients affected by post-traumatic limbal stem cell deficiency unfortunately had little prospect. Regenerative cell therapy, of which Holoclar® is a part, could revolutionize the future of these patients.

PMID 34738749
阅读全文 →
PubMedPharmacoEconomics - open2021-08-21

Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review.

Pinho-Gomes Ana-Catarina AC, Cairns John J

This review discusses the methodological challenges to the evaluation of advanced therapy medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence (NICE). We analysed the health technology appraisals (both published and in development) of ATMPs conducted by NICE in England until July 2021. A total of 14 health technology appraisals of ATMPs were included, of which two were in development and 12 had been published. There were ten gene therapy products (talimogene laherparepvec [TA410], strimvelis [HST7], tisagenlecleucel [TA554 and TA567], axicabtagene ciloleucel [TA559], voretigene neparvovec [HST11], autologous anti-CD19-transduced CD3+ cells [TA677], betibeglogene autotemcel [ID968], onasemnogene abeparvovec [HST15] and OTL-200 [ID1666]), one tissue engineered product (holoclar [TA467]) and three somatic cell therapy products (darvadstrocel [TA556] and autologous chondrocyte implantation [ACI] [TA477 and TA508]). Only three of these technologies were not recommended by NICE, although four were only recommended within the Cancer Drugs Fund. There was large uncertainty in the assessment of clinical effectiveness, as evidence relied mostly on small, single-arm, open-label studies. There were also several concerns in the cost-effectiveness evaluations, such as limited information on health-related quality of life, immature survival data due to short follow-up, and unclear curative potential. Substantial risk may be incurred with ATMPs, which have high upfront and possibly irrecoverable costs but uncertain long-term benefits. In conclusion, the challenges raised by the economic appraisal of ATMPs, albeit not unique, may be exacerbated by the uncertainty related to the often scant evidence base. Adaptations of the conventional decision-making process rather than completely new methods may improve appraisals of ATMPs.

PMID 34415514
阅读全文 →

注册免费账户还可查看另外 8 篇文献

免费注册查看全部文献 →

了解更多Holoclar